Fulcrum Therapeutics Bolsa (NASDAQ: FULC)

Últimas noticias sobre Fulcrum Therapeutics (NASDAQ:FULC) Bolsa

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

News

HALO

Evotec Confirms Receipt Of Non-binding Expression Of Interest From Halozyme Therapeutics With An Offer Price Of EUR 11.00 Per Share

PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $9.100 million which beat the analyst consensus estimate of $8.859 million by 2.72 percent. This is a 24.15 percent increase over sales of $7.330 million the same period last year.

Earnings

Earnings Beats

PEDEVCO Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $9.100M Beat $8.859M Estimate

Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) reported quarterly losses of $(4.54) per share which beat the analyst consensus estimate of $(7.12) by 36.24 percent. This is a 30.9 percent increase over losses of $(6.57) per share from the same period last year.

FBRX

Forte Biosciences Q3 EPS $(4.54) Beats $(7.12) Estimate

Jefferies analyst Omar Nokta maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Safe Bulkers, Maintains $6 Price Target

Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 47.92 percent increase over losses of $(0.48) per share from the same period last year.

RVPH

Reviva Pharmaceuticals Q3 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate

Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) reported quarterly losses of $(0.72) per share. This is a 13.25 percent increase over losses of $(0.83) per share from the same period last year. The company reported $2.62 million in sales this quarter. This is a 5.65 percent increase over sales of $2.48 million the same period last year.

NVFY

Nova Lifestyle Q3 EPS $(0.72) Up From $(0.83) YoY, Sales $2.62M Up From $2.48M YoY

Hedge Funds

General

FLUT

SPOT

ValueAct Holdings' Q3 2024 13F Filing Reveals Full Exits From Spotify, Fiserv, KKR & Co., New York Times With 1.34M Shares, And Flutter Entertainment

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.
What Happened: After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.
Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;
&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a>
Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. 
Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. 
Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
PLTR Price Action: Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Pershing Square Capital's Q3 2024 13F Filing Shows New Stakes In Brookfield Corp With 25.88M Shares, Nike With 13.24M Shares, And Seaport Entertainment Group With 2.09M Shares Each In Common Stock And Rights

RBLX

ValueAct Holdings' Q3 2024 13F Filing Indicates Increased Stakes In Walt Disney By 22% To 7.46M Shares And Roblox By 341% To 10.14M Shares

LLYVA

LLYVK

ValueAct Holdings' Q3 2024 13F Filing Shows New Stakes In Meta Platforms With 211.5K Shares, Live Nation Entertainment With 1.01M Shares, Visa With 373.6K Shares, Liberty Media Corp Series C With 1.34M Shares, And Liberty Media Corp Series A With 671.8K Shares

The loss is primarily attributable to a non-cash change in fair value of warrant liabilities related to common share price and warrant price appreciation during the quarter, production restart related operating expenses, and interest expense.

Sable Offshore Reports Q3 Net Income Of $(255.6)M

Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat the analyst consensus estimate of $1.000 million by 92.60 percent. This is a 647.65 percent increase over sales of $257.606 thousand the same period last year.

MRKR

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Telsey Advisory Group analyst Dana Telsey maintains Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) with a Market Perform and maintains $2 price target.

LVLU

Telsey Advisory Group Maintains Market Perform on Lulus Fashion Lounge, Maintains $2 Price Target

XWEL

XWELL Q3 Revenue $8.4M Up From $7.5M YoY

NNOX

NVDA

RXRX

Nvidia 13F Shows Decreased Stake In Arm Holdings By 13% From 320,823 To 280,411 Shares; Decreased Stake In Recursion Pharmaceuticals By 12% From 57,797 To 50,784 Shares; Decreased Stake In Nano X Imaging Ltd By 17% From 437 To 362 Shares

Earnings Misses

POET

POET Technologies Q3 2024 GAAP EPS $(0.20) Misses $(0.090) Estimate

Contracts

Eaton Says It Has Been Selected By MDA Space To Deliver High-performance Propellant Storage Tanks

Fulcrum reduces its workforce

Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $3.00....

Fulcrum Therapeutics (FULC) Gets a Hold from Stifel Nicolaus

Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback

Fulcrum Therapeutics GAAP EPS of -$0.35 beats by $0.05

"In the third quarter, we made progress enrolling patients and activating new sites in the Phase 1b PIONEER trial of pociredir in sickle cell disea...

Fulcrum Therapeutics reports Q3 EPS (35c), consensus (41c)

Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable secur...

Fulcrum Therapeutics expects cash to fund operations into at least 2027

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated price tar...

Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts

RBC Capital analyst Gregory Renza maintained a Hold rating on Fulcrum Therapeutics (FULC – Research Report) yesterday and set a price target of $4....

RBC Capital Remains a Hold on Fulcrum Therapeutics (FULC)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AXSM

CTXR

FULC

HRTX

MNOV

PHAT

RAPT

RGEN

SNYNF

SYRS

Press Releases

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Markets

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Health Care

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

Comments

Fulcrum Therapeutics

Noticias

Últimas noticias sobre Fulcrum Therapeutics (NASDAQ:FULC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL